Dupixent from Sanofi S.A. - eczema biologic reshapes US treatment habits

By Nora Whitfield, ad hoc news Lifestyle & Consumer Desk. Reviewed July 03, 2026, 9:20 AM ET. Details in the imprint.

Dupixent is the kind of drug you notice before you ever read the label: the nurse cracks open the chilled carton, the prefilled pen clicks, and someone who has scratched through their bedsheets finally has a shot at sleeping through the night. In US allergy clinics and dermatologist offices from Phoenix to Philadelphia, Sanofi’s biologic has turned into a regular Friday-afternoon ritual for patients with eczema so severe that steroid creams barely made a dent.

What Dupixent does in real life

On paper, Dupixent (generic name dupilumab) is an injectable monoclonal antibody that blocks two key inflammatory pathways, IL-4 and IL-13, to treat moderate to severe atopic dermatitis in adults and children six months and older. In real life, it shows up as fewer bloody pillowcases, less stares on the subway, and parents finally tossing out the stack of cotton gloves their kids wore to keep from scratching.

Sanofi, together with Regeneron Pharmaceuticals, markets Dupixent across a growing list of indications in the US, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and prurigo nodularis. The US Food and Drug Administration first approved it for adults with atopic dermatitis in 2017, and since then the label has expanded step by step down into pediatric age groups and across inflammatory diseases.

How you get Dupixent in the US

In the US, Dupixent is prescription-only and dispensed as prefilled pens or syringes that patients or caregivers can inject at home after a few training sessions with a nurse. The drug must be stored refrigerated and brought to room temperature before injection, a ritual many users know well: take the pen out of the fridge, wait 45 minutes on the kitchen counter, then press it into the thigh or abdomen until the click stops.

List prices are high. Sanofi’s US site shows an approximate annual wholesale acquisition cost in the tens of thousands of dollars for adults, depending on dose and indication. But that headline number is softened by insurance coverage: Dupixent is reimbursed by most major commercial plans and Medicare Part D, and Sanofi advertises copay assistance and patient-support programs that can bring out-of-pocket costs below 100 dollars per month for eligible patients.

Behind the scenes: a biologic workhorse

For Sanofi’s immunology head, Dr. John Reed, Dupixent has become a textbook example of a franchise built around a single mechanism with many disease doors. By targeting IL-4 and IL-13 signaling, the drug dampens type 2 inflammation that underlies eczema, some forms of asthma, nasal polyps and other conditions. That biological focus lets Sanofi test indications one by one while leaning on a growing safety database.

Clinical trial data published in journals such as The New England Journal of Medicine show that Dupixent can cut eczema severity scores by more than half in many patients and sharply reduce itch. In one adult atopic dermatitis trial, roughly 38 percent of patients achieved clear or almost clear skin at 16 weeks compared with 10 percent on placebo, a difference that regulators and payers latched onto. Real-world data from registries and claims databases now back up those findings with longer-term evidence, including reduced hospitalizations for serious skin infections.

US patients and doctors: how it fits into care

In US practice, Dupixent is usually reserved for cases where topical steroids, calcineurin inhibitors and moisturizer regimens have failed or where the disease is widespread enough to justify systemic therapy. Allergists and dermatologists talk about it as a shift away from broad immunosuppressants like cyclosporine toward more targeted biologics that spare the rest of the immune system. For families juggling school, work and nighttime flares, that nuance matters less than the simple metric of “how many hours did my child sleep this week.”

Dr. Emma Guttman-Yassky, a leading atopic dermatitis specialist in New York, has described Dupixent as bringing a “new era of disease control” for many patients, while still stressing that not everyone responds. Around 10 to 20 percent in trials saw limited benefit, and injections can cause conjunctivitis and injection-site reactions that some users find hard to tolerate. That ceiling keeps pressure on Sanofi to refine dosing, expand formulation options and stay ahead of competitors from AbbVie, Eli Lilly and others targeting adjacent inflammatory pathways.

Pricing, insurance and the US wallet impact

For US consumers, the financial story matters almost as much as the clinical one. A single Dupixent pen for atopic dermatitis can carry a list price in the 3,000 to 4,000 dollar range before discounts, depending on dose and distribution channel. Annual therapy costs often run above 30,000 dollars at wholesale rates, a number most patients only encounter through headlines, not actual bills.

After rebates and insurance-negotiated discounts, payer data suggest the net cost to health plans can be significantly lower. Sanofi runs a Dupixent MyWay support program that helps coordinate prior authorization, offers copay cards for commercially insured patients and provides free drug for some uninsured or underinsured individuals who meet income criteria. That ecosystem is not simple; many families still report fights with their health plan every prior-authorization cycle. But for a biologic with such high nominal pricing, broad coverage is the only way it reaches the kind of 1-million-patient global milestone Sanofi cites in its materials.

Regulatory status and new indications

From the regulatory side, the US FDA has cleared Dupixent for an expanding set of indications since the first atopic dermatitis nod in March 2017. Subsequent approvals covered moderate to severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and prurigo nodularis. Each addition opens new prescriber bases: pulmonologists for asthma, ENT surgeons for nasal polyps, gastroenterologists for esophageal disease.

Recent US regulatory news has centered on expanded pediatric use and new data in chronic obstructive pulmonary disease (COPD) with type 2 inflammation, an area where Sanofi and Regeneron reported positive Phase 3 results and have filed for approval. If the FDA signs off, Dupixent could tap another chronic disease pool in US adults where exacerbations and hospitalizations carry high clinical and economic costs. That potential is one reason analysts on Wall Street and in Paris track every trial readout and advisory-committee date closely.

Competition and the broader eczema market

Sanofi is not alone in the eczema-biologic space. AbbVie’s Rinvoq, Eli Lilly’s Olumiant and JAK inhibitors from other players offer oral alternatives that some patients prefer over injections. Small-molecule drugs can reach compartments that injectable antibodies may miss, but they come with their own risk profiles, including boxed warnings for serious infections and malignancies in some cases. For now, Dupixent’s safety and efficacy record has kept it front-of-mind for many US dermatologists as a first biologic option in moderate to severe disease.

Market-research reports point to steady growth in the global atopic dermatitis drug market, with biologics and targeted therapies taking a larger slice of the pie. In the US, that translates into more branded TV ads, more copay cards stuffed in clinic drawers and more direct-to-consumer messaging about “freedom from itch.” For retail investors, it means a tangible product story behind the abstract revenue figures on quarterly slides.

What retail investors should watch

For US retail investors and consumers reading this, the key Dupixent story is simple: a biologic that has already become a staple in eczema and allied diseases, but still has room to grow in indications and geographies. Sanofi’s CEO Paul Hudson has repeatedly pointed to Dupixent as a central growth pillar in earnings calls, citing its strong double-digit sales trajectory and the ambition to reach multi-billion-euro annual revenue. That makes every US regulatory step and competitive launch relevant well beyond dermatology journals.

Sanofi S.A. stock (NASDAQ: SNY) is US-listed as an ADR, giving American investors direct exposure to the Dupixent franchise alongside the rest of Sanofi’s vaccine, specialty-care and general-medicines portfolio. One look at the product’s weight in segment reporting shows why many analysts treat Dupixent as a bellwether for the company’s medium-term growth profile.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.